Shots:

• Bayer and Aignostics enter into a strategic collaboration, utilizing the latter's technology & longitudinal, multimodal patient’s clinical data to discover at least 2 oncology targets & expedite their development
• The partnership will further develop a target identification platform using Aignostics’ technology & Bayer’s oncology expertise. Additionally, the companies will create AI & ML based pathology algorithms that will combine baseline pathology data with clinical data for easy patient identification, stratification & selection for clinical evaluations
• Aignostics gains an undisclosed up front, payment on achieving milestones plus royalties for any commercialized targets discovered under the collaboration

Ref: Bayer | Image: Bayer

Related News:- Bayer and BridgeBio Collaborate to Commercialize Acoramidis for Treating Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Europe

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com